Efficacy of netakimab in key psoriatic arthritis domains: 54-week results from the phase III BCD-085-8/PATERA study

Netakimab is a humanized anti-interleukin-17А monoclonal antibody approved for the treatment of psoriatic arthritis, ankylosing spondylitis, moderate to severe psoriasis. Herein, we report the accumulated efficacy data and safety findings of 54-week netakimab treatment during the PATERA study.The ai...

全面介紹

書目詳細資料

Principais autores:	T. V. Korotaeva, V. I. Mazurov, A. M. Lila, I. Z. Gaydukova, A. L. Bakulev, A. V. Samtsov, V. R. Khairutdinov, A. V. Zinkina-Orikhan, Yu. A. Sevastyanova, A. V. Eremeeva
格式:	Artigo
語言:	Russo
出版:	IMA PRESS LLC 2021-03-01
叢編:	Научно-практическая ревматология
主題:	netakimab psoriatic arthritis interleukin-17 inhibitors
在線閱讀:	https://rsp.mediar-press.net/rsp/article/view/2989
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!